Impact on Pulmonary Function in a Randomized Trial of Single-Fraction and Multifraction Stereotactic Body Radiation Therapy for Pulmonary Oligometastatic Disease: An Analysis of TROG 13.01 (SAFRON II)
Publication Name
International Journal of Radiation Oncology Biology Physics
Abstract
Purpose: The TROG 13.01 (SAFRON II) trial was a phase 2 multicenter trial comparing single-fraction (SF) and multifraction (MF) stereotactic body radiation therapy. Patients with 1 to 3 peripheral pulmonary oligometastases were randomized 1:1 between 28 Gy in 1 fraction and 48 Gy in 4 fractions. There were no differences between arms in efficacy or toxicity. We performed an analysis to assess changes in pulmonary function tests (PFTs) between arms over time and assessed the effect of the number and total volume of targets on PFT change over time. Methods and Materials: A linear mixed model was used to describe the PFTs by treatment arm over time. The effect of number and volume of targets on PFTs at 6 and 12 months was assessed by a simple linear model. Results: Ninety patients were randomized; 87 were treated for 133 pulmonary oligometastases. Forty-four were randomized to the SF arm and 43 to the MF arm. There were no differences in absolute or relative PFT measures of forced expiratory volume in 1 second (FEV1), diffusing capacity of the lungs for carbon monoxide (DLCO), or forced vital capacity (FVC) between the 2 arms. At 12 months, there was a reduction in absolute DLCO from baseline (–1.7 mL/min/mm Hg [95% CI, −2.5 to −1.0]), relative DLCO (−5.5% [95% CI, −8.4% to −2.6%]), absolute FEV1 (−0.17 L [95% CI, −0.23 to −0.11]), and absolute FVC (−0.20 L [95% CI, −0.27 to −0.13]). In patients with multiple pulmonary targets, increase in target number (per lesion) was associated with a reduction in the absolute FEV1 at 6 months of −0.10 L (95% CI, −0.18 to −0.03; P = .007), FEV1 at 12 months of −0.10 L (95% CI, −0.20 to −0.01; P = .04), FVC at 6 months of −0.11 L (95% CI, −0.20 to −0.03; P = .014), and FVC at 24 months of −0.13 L (95% CI, −0.25 to −0.01; P = .036). Reduction in FEV1 was also seen per 10-mL increase in PTV at 12 months (−0.03 L [95% CI, −0.06 to −0.00], P = .036). The number of targets and PTV were not associated with DLCO. Conclusions: Treating multiple targets resulted in increased loss of FEV1 and FVC but not DLCO. There were no significant differences in PFT decline between SF and MF stereotactic body radiation therapy.
Open Access Status
This publication may be available as open access
Volume
118
Issue
4
First Page
944
Last Page
951